Provided by Tiger Trade Technology Pte. Ltd.

Kymera Therapeutics, Inc.

113.15
-1.4800-1.29%
Post-market: 112.00-1.1500-1.02%19:30 EDT
Volume:900.98K
Turnover:101.59M
Market Cap:9.41B
PE:-35.23
High:114.50
Open:114.50
Low:110.29
Close:114.63
52wk High:130.05
52wk Low:47.86
Shares:83.15M
Float Shares:64.87M
Volume Ratio:1.40
T/O Rate:1.39%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.2122
EPS(LYR):-3.6900
ROE:-24.15%
ROA:-15.59%
PB:6.23
PE(LYR):-30.66

Loading ...

Kymera Therapeutics - Kt-621 Breadth Phase 2B Asthma Trial Data Expected in Late 2027

THOMSON REUTERS
·
Jun 25

Kymera Therapeutics Completes Enrollment in the Phase 2B Broaden2 Trial of Kt-621 in Atopic Dermatitis with Topline Data by Year-end 2026

THOMSON REUTERS
·
Jun 25

Kymera Therapeutics Shareholders Elect Booth, Mainolfi, Maraganore, Ridloff as Class III Directors

Reuters
·
Jun 25

Kymera Therapeutics Names Felix Baker Board Chairman, Replacing Bruce Booth

Reuters
·
Jun 25

Kymera Therapeutics Appoints Felix J. Baker, Ph.d., as Chairman of the Board of Directors

THOMSON REUTERS
·
Jun 25

Kymera Therapeutics Chief Business Officer Noah Goodman reports sale of 2,500 shares worth $247,500

Reuters
·
Jun 23

Kymera Therapeutics (KYMR) Receives a Buy from Barclays

TIPRANKS
·
Jun 22

Kymera Therapeutics participates in a conference call with JPMorgan

TIPRANKS
·
Jun 18

Why Kymera Therapeutics (KYMR) Is Up 16.6% After Positive KT-621 Phase 1 Japanese Data

Simply Wall St.
·
Jun 16

Kymera reports Phase 1 data in healthy Japanese adults for KT-621 oral STAT6 degrader

Reuters
·
Jun 12

Kymera Therapeutics posts corporate presentation outlining oral immunology protein degrader pipeline

Reuters
·
Jun 09

Kymera Therapeutics, Sanofi dose first participant in Phase 1 trial of IRAK4 degrader KT-485

Reuters
·
Jun 09

Kymera Therapeutics Announces First Participant Dosed in Phase 1 Trial of Oral Irak4 Degrader, KT-485, and Milestone Achievement Under Sanofi Collaboration

THOMSON REUTERS
·
Jun 09

Kymera Therapeutics - Eligible for up to $975 Mln in KT-485 Milestones

THOMSON REUTERS
·
Jun 09

Kymera Therapeutics - Receive S $20 Mln Milestone Payment From Sanofi

THOMSON REUTERS
·
Jun 09

Kymera Therapeutics: Buy Rating Reiterated as Analyst Maintains $110 Price Target on Emerging Protein Degrader Pipeline

TIPRANKS
·
Jun 09

Kymera Therapeutics COO Chadwick to Retire

Dow Jones
·
Jun 09

Kymera Therapeutics COO Resigns, Transition Plan Implemented

TIPRANKS
·
Jun 09

Kymera Therapeutics names Penny Carlson SVP, Development Operations

Reuters
·
Jun 09

Kymera Therapeutics Appoints Penny Carlson as Senior Vice President, Development Operations

THOMSON REUTERS
·
Jun 09